ISIS Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 12.11B 10.45B 9.62B 9.03B 16.94B 1,147B 17.13B 114B 44.38B 560B 45.44B 44.47B 1,941B | P/E Ratio 2026 * |
-20.3x | P/E Ratio 2027 * | -57x |
|---|---|---|---|---|---|
| Enterprise Value | 11.89B 10.26B 9.45B 8.86B 16.63B 1,126B 16.81B 112B 43.56B 550B 44.61B 43.66B 1,905B | EV / Sales 2026 * |
13.4x | EV / Sales 2027 * | 8.02x |
| Free-Float |
99.08% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 12.11B | |
| +0.96% | +1.94% | -12.97% | -13.01% | 43.03B | |
| +4.02% | +7.26% | +294.33% | +533.90% | 32.71B | |
| -1.69% | -2.76% | +13.70% | -16.14% | 30.29B | |
| +1.41% | -0.70% | -0.53% | +28.87% | 29.4B | |
| +1.16% | +2.10% | +14.27% | +22.05% | 25.08B | |
| +2.40% | +6.10% | - | - | 13.54B | |
| +0.03% | +2.92% | +56.75% | +114.15% | 13.35B | |
| -1.09% | -2.37% | +5.07% | +5.25% | 12.97B | |
| +1.05% | -1.16% | +1.41% | -35.92% | 11.19B | |
| Average | +0.49% | +0.76% | +46.50% | +79.89% | 23.51B | |
| Weighted average by Cap. | +0.38% | +0.80% | +53.87% | +95.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 890M 768M 707M 664M 1.25B 84.31B 1.26B 8.36B 3.26B 41.18B 3.34B 3.27B 143B | 1.49B 1.29B 1.19B 1.11B 2.09B 142B 2.11B 14.04B 5.48B 69.13B 5.61B 5.49B 240B |
| Net income | -595M -513M -472M -443M -832M -56.31B -841M -5.59B -2.18B -27.51B -2.23B -2.18B -95.31B | -215M -185M -171M -160M -301M -20.35B -304M -2.02B -788M -9.94B -806M -789M -34.45B |
| Net Debt | -222M -191M -176M -165M -310M -21.01B -314M -2.08B -813M -10.26B -832M -815M -35.55B | -130M -112M -103M -97.09M -182M -12.33B -184M -1.22B -477M -6.02B -489M -478M -20.87B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
